Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Dimopoulos, Meletios A.
  • Moreau, Philippe
  • Augustson, Bradley
  • Castro, Nelson
  • Pika, Tomas
  • Delimpasi, Sosana
  • Maiolino, Angelo
  • Reiman, Tony
  • Martinez-Lopez, Joaquin
  • Martin, Thomas
  • Mikhael, Joseph
  • Yong, Kwee
  • Risse, Marie-Laure
  • Asset, Gaelle
  • Marion, Sylvia
  • Hajek, Roman

Grupos

Abstract

[No abstract available]

Datos de la publicación

ISSN/ISSNe:
0361-8609, 1096-8652

AMERICAN JOURNAL OF HEMATOLOGY  WILEY

Tipo:
Article
Páginas:
15-19
PubMed:
35604280
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
2,600 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 21

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • bortezomib; carfilzomib; dexamethasone; isatuximab; lenalidomide; antineoplastic agent; monoclonal antibody; age; aged; arthralgia; bronchitis; cancer recurrence; cancer staging; constipation; controlled study; coughing; diarrhea; drug efficacy; drug response; drug safety; drug withdrawal; dyspnea; fatigue; human; hypertension; infusion related reaction; Letter; line of treatment; major clinical study; minimal residual disease; multiple cycle treatment; multiple myeloma; nausea; pneumonia; progression free survival; treatment duration; upper respiratory tract infection; vomiting; tumor recurrence; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local

Campos de Estudio

Cita

Compartir